| abstract |
PROBLEM TO BE SOLVED: To provide a bispecific antibody and a chemotherapeutic agent in which an antigen binding site targeting death receptor 5 (DR5) and a second antigen binding site targeting a fibroblast activation protein (FAP) are combined. Provided is a method of using the bispecific antibody in combination. DR5 and FAP comprising at least one DR5-specific antigen-binding site and at least one FAP-specific antigen-binding site for use as a combination therapy in a method of treating cancer. Bispecific antibody that binds to irinotecan, doxorubicin, oxaliplatin, 5-FU, MDM2 inhibitor, Bcl-2 inhibitor, abraxane, paclitaxel, gemcitabine, voltezomib, cyclopamine, PARP inhibitor, ifosphamide or anti A bispecific antibody used in combination with a chemotherapeutic agent selected from VEGF antibodies. [Selection diagram] None |